A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Aug 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Johnson & Johnson
- 27 Jul 2017 Planned End Date changed from 31 Mar 2020 to 1 Aug 2018.
- 27 Jul 2017 Planned initiation date changed from 5 Jul 2017 to 15 Jan 2018.
- 21 Jun 2017 New trial record